Literature DB >> 23498154

Has the prevalence, clinical presentation and social functioning of schizophrenia changed over the last 25 years? Nithsdale schizophrenia survey revisited.

Somashekara Shivashankar1, Susan Telfer, Jeyarani Arunagiriraj, Matthew McKinnon, Sameer Jauhar, Rajeev Krishnadas, Robin McCreadie.   

Abstract

BACKGROUND: Major changes in the treatment of schizophrenia have taken place in recent years, including a shift from inpatient to community care, and the introduction of second-generation antipsychotics and psychosocial interventions. Recent evidence has questioned the superiority of these interventions over older treatments. AIMS: We wished to ascertain the impact of changes in the treatment of schizophrenia in a geographically-defined area, focusing on clinical symptoms and psychosocial outcome.
METHODS: In 2006, we replicated the survey carried out in 1981, identifying the population of people with schizophrenia living in Nithsdale, South-West Scotland, measuring prevalence using the 'key informant' method. We assessed their clinical and social functioning, using similar scales, and compared measures across both time periods.
RESULTS: We identified 205 people with schizophrenia, a point prevalence of 3.59/1000 general population. In 2006, while fewer people experienced negative symptoms, a greater number experienced positive symptoms. There were no significant differences in the prevalence of tardive dyskinesia or Parkinsonism, though tremor was less common in the 2006 population. In 2006, there were fewer people living with a spouse/partner or parents, and fewer were in open employment in comparison to the 1981 population. The overall level of social adjustment had not changed.
CONCLUSIONS: The clinical manifestation of schizophrenia appears to have changed over the last 25 years, within this geographically-defined area, the prevalence of negative symptoms having decreased, and positive symptoms seem to have increased. The level of social functioning does not appear to have changed over the last 25 years.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23498154     DOI: 10.1016/j.schres.2013.02.006

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  One-year randomized controlled trial and follow-up of integrated neurocognitive therapy for schizophrenia outpatients.

Authors:  Daniel R Mueller; Stefanie J Schmidt; Volker Roder
Journal:  Schizophr Bull       Date:  2015-02-22       Impact factor: 9.306

2.  Hospitalization and Some Sociodemographic Characteristics of Patients Registered with a Community Mental Health Center.

Authors:  Etem Erdal Erşan
Journal:  Community Ment Health J       Date:  2019-11-16

3.  Longer Duration of Untreated Psychosis Hinders Improvement in Treatment of Chronic Schizophrenia: Community Based Early Intervention is an Evidence Based Option.

Authors:  Abdülkadir Tabo; Erkan Aydın; Hüseyin Yumrukçal; Sadık Yiğit; Uğraş Erman Uzun; Oğuz Karamustafalıoğlu
Journal:  Community Ment Health J       Date:  2017-02-10

4.  A randomized clinical trial to test the efficacy of a family-focused, culturally informed therapy for schizophrenia.

Authors:  Amy Weisman de Mamani; Marc J Weintraub; Kayla Gurak; Jessica Maura
Journal:  J Fam Psychol       Date:  2014-10-06

5.  Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia.

Authors:  Ahmad Ghanizadeh; Michael Berk
Journal:  Med Gas Res       Date:  2013-06-06

Review 6.  Neurodevelopmental and environmental hypotheses of negative symptoms of schizophrenia.

Authors:  Frédéric Limosin
Journal:  BMC Psychiatry       Date:  2014-03-26       Impact factor: 3.630

7.  Exome sequence analysis and follow up genotyping implicates rare ULK1 variants to be involved in susceptibility to schizophrenia.

Authors:  Mariam M Al Eissa; Alessia Fiorentino; Sally I Sharp; Niamh L O'Brien; Kate Wolfe; Giovanni Giaroli; David Curtis; Nicholas J Bass; Andrew McQuillin
Journal:  Ann Hum Genet       Date:  2017-11-17       Impact factor: 1.670

8.  Atypical Antipsychotics Mediate Dynamics of Intrinsic Brain Activity in Early-Stage Schizophrenia? A Preliminary Study.

Authors:  Yingchan Wang; Yuchao Jiang; Dengtang Liu; Jianye Zhang; Dezhong Yao; Cheng Luo; Jijun Wang
Journal:  Psychiatry Investig       Date:  2021-12-23       Impact factor: 2.505

Review 9.  An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review.

Authors:  Jason C Simeone; Alexandra J Ward; Philip Rotella; Jenna Collins; Ricarda Windisch
Journal:  BMC Psychiatry       Date:  2015-08-12       Impact factor: 3.630

Review 10.  Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses.

Authors:  Berta Moreno-Küstner; Carlos Martín; Loly Pastor
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.